Interactions between buspar-dividose(busPIRone) and Marplan (isocarboxazid)
busPIRone and isocarboxazid (Major Drug-Drug)
CONTRAINDICATED: Monoamine oxidase inhibitors (MAOIs) may potentiate the activity of serotonergic agents such as serotonin reuptake inhibitors, 5-HT1 receptor agonists, ergot alkaloids, buspirone, dextromethorphan, and most antidepressants. The result may be an increased risk of serotonin syndrome, which is a rare but serious and potentially fatal condition thought to result from hyperstimulation of brainstem 5HT1A receptors and characterized by symptoms such as CNS irritability, altered consciousness, confusion, myoclonus, ataxia, abdominal cramping, hyperpyrexia, shivering, pupillary dilation, diaphoresis, hypertension, and tachycardia. The mechanism is an additive pharmacodynamic effect resulting from MAOI inhibition of serotonin metabolism.
MANAGEMENT: In general, serotonergic agents should not be used concurrently with MAOIs or other agents that possess MAOI activity (e.g., furazolidone, procarbazine). At least 14 days should elapse between discontinuation of MAOI therapy and initiation of treatment with serotonergic agents. A washout period of 7 to 14 days minimum is recommended when switching from another antidepressant to an MAOI.
